TY  - JOUR
AU  - Mc Laughlin, Anna M
AU  - Hertz, Daniel L
AU  - Novillo Villajos, Apolonia
PY  - 2024
DO  - 10.1002/cpt.3238
SN  - 0009-9236
SN  - 1532-6535
UR  - https://hdl.handle.net/20.500.14352/130303
T2  - Clinical Pharmacology & Therapeutics
AB  - Tamoxifen is widely used in patients with hormone receptor-positive breast cancer. The polymorphic enzyme CYP2D6 is primarily responsible for metabolic activation of tamoxifen, resulting in substantial interindividual variability of plasma...
LA  - eng
M2  - 690
PB  - Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
KW  - Z-endoxifen
KW  - tamoxifen
KW  - CEPAM cohort
KW  - CYP2D6
KW  - Breast cancer
TI  - Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort
TY  - journal article
VL  - 116
ER  -